Fungal nail infection: Assessing the new treatment options

Cleveland Clinic Journal of Medicine

Volumn 70, Issue 2, 2003, Pages 110-118

  Botek, Georgeanne ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ASTEMIZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; CICLOPIROXOLAMINE; CIMETIDINE; CISAPRIDE; CYCLOSPORIN; DIGOXIN; DOFETILIDE; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MIDAZOLAM; MONOAMINE OXIDASE INHIBITOR; PHENYTOIN; PIMOZIDE; QUINIDINE; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; TERBINAFINE; TERFENADINE; THEOPHYLLINE; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT;

AGING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEBRIDEMENT; DISEASE CLASSIFICATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HEPATOBILIARY DISEASE; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; ONYCHOMYCOSIS; PATIENT EDUCATION; PRESCRIPTION; PREVALENCE; REVIEW; SKIN MANIFESTATION; TASTE DISORDER; TOPICAL TREATMENT;

EID: 0037293524     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.70.2.110     Document Type: Review

References (28)

1. Drake LA, Patrick DL, Fleckman P, et al. The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. J Am Acad Dermatol 1999; 41:189-196.
2. Havu V, Heikkila H, Kuokkanen K, et al. A double-blind, randomized study to compare the efficacy and safety of terbinafine with fluconazole in the treatment of onychomycosis. Br J Dermatol 2000; 142:97-102.
3. Charif MA, Elewski BE. Prevalence of onychomycosis in the United States: results of a population-based survey [abstract]. Presented at the 1996 Annual Meeting of the Society for Investigative Dermatology. Washington, DC, May 1-5, 1996.
4. Drake LA, Scher RK, Smith EB, et al. Effect of onychomycosis on quality of life. J Am Acad Dermatol 1998; 38:702-704.
5. Scher RK. Onychomycosis: therapeutic update. J Am Acad Dermatol 1999; 40:S21-S26.
6. Elewski BE, Charif MA, Daniel CR 3rd. Onychomycosis. In: Scher RK, Daniel CR III, editors. Nails: Diagnosis, Treatment, Surgery, 2nd ed. Philadelphia: WB Saunders, 1997:151-162.
7. Baran R, Hay RJ, Tosti A, Haneke E. A new classification of onychomycosis. Br J Dermatol 1998; 139:567-571.
8. Gupta AK, Baran R. Ciclopirox nail lacquer solution 8% in the 21st century. J Am Acad Dermatol 2000; 43:S96-S102.
9. Gupta AK, Jain HC, Lynde CW, Watteel GN, Summerbell RC. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada: a multicenter survey of 2001 patients. Int J Dermatol 1997; 36:783-787.
10. Gupta AK, Summerbell RC. Combined distal and lateral subungual and white superficial onychomycosis in the toenails. J Am Acad Dermatol 1999; 41:938-944.
11. Baran R, Dawber RPR, Tosti A, Haneke E. Onychomycosis and its treatment. In: Baran R, Dawber R, Haneke E, Tosti A. A Text Atlas of Nail Disorders: Diagnosis and Treatment. London: Martin Dunitz, 1996:155-168.
12. Greer DL. Evolving role of nondermatophytes in onychomycosis. Int J Dermatol 1995; 34:521-528.
13. Leib SL. Recurrent erysipelas, tinea pedis et unguium, chronic venous insufficiency. Schweiz Rundsch Med Prax 1994; 83:1089-1090.
14. Sehgal VN, Jain S. Onychomycosis: clinical perspective. Int J Dermatol 2000; 39:241-249.
15. Sorenson GW, Jones HE. Immediate and delayed hypersensitivity in chronic dermatophytosis. Arch Dermatol 1976; 112:40-42.
16. Blake JS, Dahl MV, Herron MJ, Nelon RD. An immunoinhibitory cell wall glycoprotein from Trichophyton rubrum. J Invest Dermatol 1991; 96:657-661.
17. MacCarthy KG, Blake JS, Johnson KL, et al. Dermatophyte-responsive T-cell lines recognize cross reactive antigens associated with mannose-rich glycoproteins. Exp Dermatol 1994; 3:66-71.
18. Lubeck DP, Patrick DL, McNulty P, Fifer SK, Birnbaum J. Quality of life of persons with onychomycosis. Qual Life Res 1993; 2:341-348.
19. Markinson BC, Monter SI, Cabrera G. Traditional approaches to treatment of onychomycosis. J Am Podiatr Med Assoc 1997; 87:551-556.
20. Joseph WS. Oral treatment options for onychomycosis. J Am Podiatr Med Assoc 1997; 87:520-531.
21. 1997 Diabetes survey. Statistical results. Al Fisher Associates, Inc. J Am Podiatr Med Assoc 1997; 87:575-582.
22. Jain S, Sehgal VN. Onychomycosis: treatment perspective. Int J Dermatol 2000; 39:10-14.
23. Tosti A, Piraccini BM, Stinchi C, Colombo MD. Relapses of onychomycosis after successful treatment with systemic antifungals: a 3-year follow-up. Dermatology 1998; 197:162-166.
24. Gupta AK, Shear NH. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Safety 2000; 22:1-52.
25. Hay RJ. Risk-benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993; 29:S50-S54.
26. Gupta AK, Shear NH. The new oral antifungal agents for onychomycosis of the toenails. J Eur Acad Dermatol Venereol 1999; 13:1-13.
27. Schatz F, Brautigam M, Dobrowolski E, et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 1995; 20:377-383.
28. Gupta AK, Joseph WS. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. J Am Podiatr Med Assoc 2000; 90:495-501.